A Study of KT-621 Administered Orally to Adult Participants With Moderate to Severe Eosinophilic Asthma

ClinicalTrials.gov ID: NCT07323654

Public ClinicalTrials.gov record NCT07323654. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.

View official ClinicalTrials.gov record → Back to search

ClinicalTrials.gov public records Last synced May 20, 2026, 10:02 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Official title

A Phase 2b, Randomized, Double-blind, Placebo-controlled, Parallel-group, Multicenter, Dose-ranging Study Investigating the Efficacy and Safety Profile of KT-621 Administered Orally to Adult Participants With Uncontrolled Moderate to Severe Eosinophilic Asthma

Study identification

NCT ID: NCT07323654
Recruitment status: Recruiting
Study type: Interventional
Phase: Phase 2
Lead sponsor: Kymera Therapeutics, Inc.; Industry
Enrollment: 264 participants

Conditions and interventions

Conditions

Eosinophilic Asthma

Interventions

KT-621 Drug
Placebo Other

Drug · Other

Eligibility (public fields only)

Age range: 18 Years to 75 Years
Sex: All
Healthy volunteers: Healthy volunteers not accepted

This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.

Study timeline

Start date: Jan 27, 2026
Primary completion: Nov 30, 2027
Completion: Nov 30, 2027
Last update posted: May 17, 2026

2026 – 2027

United States locations

U.S. sites: 20
U.S. states: 12
U.S. cities: 19

Facility	City	State	ZIP	Site status
Kymera Investigative Site	Long Beach	California	90815	Recruiting
Kymera Investigative Site	Northridge	California	91324	Recruiting
Kymera Investigative Site	Redding	California	96001	Recruiting
Kymera Investigative Site	Upland	California	91786	Recruiting
Kymera Investigative Site	Loxahatchee Groves	Florida	33470	Recruiting
Kymera Investigative Site	Miami	Florida	33126	Recruiting
Kymera Investigative Site	Miami	Florida	33173	Recruiting
Kymera Investigative Site	Tampa	Florida	33607	Recruiting
Kymera Investigative Site	East Point	Georgia	30344	Recruiting
Kymera Investigative Site	Iowa City	Iowa	52242	Recruiting
Kymera Investigative Site	Chapel Hill	North Carolina	27517	Recruiting
Kymera Investigative Site	Toledo	Ohio	43617	Recruiting
Kymera Investigative Site	Edmond	Oklahoma	73034	Recruiting
Kymera Investigative Site	Clackamas	Oregon	97015	Recruiting
Kymera Investigative Site	Pittsburgh	Pennsylvania	15241	Recruiting
Kymera Investigative Site	North Charleston	South Carolina	29406	Recruiting
Kymera Investigative Site	Rock Hill	South Carolina	29732	Recruiting
Kymera Investigative Site	Chattanooga	Tennessee	37403	Recruiting
Kymera Investigative Site	Dallas	Texas	75209	Recruiting
Kymera Investigative Site	McKinney	Texas	75069	Recruiting

Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.

Non-U.S. locations

This page focuses on the U.S. directory. The official record also lists 7 non-U.S. sites.

About this trial record page

What this page shows: Public field values for ClinicalTrials.gov record NCT07323654, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
What this page does not do: No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
Where the data comes from: Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
Last refresh: Last update posted May 17, 2026 · Synced May 20, 2026

Open the official record

The complete protocol, eligibility criteria, and contact information for NCT07323654 live on ClinicalTrials.gov.

View official ClinicalTrials.gov record →